Evusheld Billing and Coding Update
There is a new product code for the 600 mg dosing regimen of Evusheld (Q0221). The product code is effective from the date of the FDA EUA update, February 24, 2022.
The original product code (Q0220 for 300 mg) is still effective and can be used for “catch up” doses.
For more information, providers can view the CMS COVID-19 Vaccines and Monoclonal Antibodies or the AstraZeneca Evusheld Coding Resource.
HRSA Uninsured Program Ends
On March 22, 2022 at 11:59 pm ET, the Uninsured Program stopped accepting claims for testing and treatment due to lack of sufficient federal funds.
For more information, providers can view the COVID-19 Uninsured Program Claims Submission Deadline FAQs.
Reminder: Change in Paxlovid and Molnupiravir Allocation Process
DSHS now allocates Paxlovid and/or molnupiravir based on emailed requests instead of doing case-based allocations and automatic ordering/shipping.
To obtain additional Paxlovid and/or molnupiravir for your facility, please email therapeutics@dshs.texas.gov with the number of courses requested of the specified product.
- Please include the full name of the facility and HPOP State PIN (e.g., TXA123456)
- Request quantities in multiples of 20 for Paxlovid and 24 for molnupiravir.
- Inventory reporting in HPOP must be current.
-
These are requests. Oral antivirals are subject to allocation and the request may not be filled in full.
-
Please email requests by 5:00PM on Thursday to be included in the following week’s allocation
Note: sites must have a Texas pharmacy license to be eligible to receive antiviral medication.
Reminder: Evusheld Request Process
Providers enrolled to provide Evusheld may request this product by emailing therapeutics@dshs.texas.gov with the number of cartons they would like to request. Requests must be in multiples of 24 cartons (1 carton = 150 mg tixagevimab plus 150 mg cilgavimab).
Reminder: Evusheld Reporting Updates
Please report inventory and administration of Evusheld in HPOP by cartons (150 mg tixagevimab/150 mg cilgavimab).
The patient receiving the larger initial dose (300 mg each of tixagevimab/cilgavimab) would be reported as two units (cartons or courses) administered. The patient receiving the smaller dose (150 mg tixagevimab/150 mg cilgavimab) would be reported as one unit administered.
For more information on HPOP reporting, visit the HPOP FAQ for COVID-19 Therapeutics Providers or contact therapeutics@dshs.texas.gov.
Update: Bamlanivimab Expiration
Certain courses of bamlanivimab are due to expire soon. This includes lots that previously had their expiration dates extended. Providers should confirm the expiration dates of any expired product with the manufacturer. Providers should follow the instructions of the manufacturer as to whether to ship the expired product back or waste it on-site.
Providers with questions about BAM/ETE can contact the manufacturer, Lilly, at 1-855-545-5921. Providers with questions about REGEN-COV can contact Regeneron at 844-734-6643.
There is currently no platform for providers to report waste for BAM/ETE, REGEN-COV, or Sotrovimab.
Reminder: Enter HPOP State PIN in Therapeutics Order Request Form
When requesting COVID-19 monoclonal antibodies in the Vaccine Allocation & Ordering System (VAOS), providers who have an HPOP State PIN should enter the numbers from it in the Amerisource Bergen Account Number field.
For example, if your HPOP State PIN is TXA123456, enter 123456. Providers who do not have an HPOP account should contact therapeutics@dshs.texas.gov to enroll.
Expert Tip: Therapeutics Product Guide
To understand which therapeutics are available through DSHS and how to request them, please visit the therapeutics product guide. This aid providers updated guidance on product availability, request methods, reporting requirements, and other relevant details and resources.
|
